曲前列尼尔减轻大鼠肾脏缺血再灌注损伤的临床前研究
该研究在大鼠双侧肾缺血45分钟再灌注模型中,于缺血前18-24小时皮下给予曲前列尼尔(100 ng/kg/min)或安慰剂。结果显示曲前列尼尔显著降低血肌酐和尿素氮峰值并加速其恢复至基线,减轻肾小管上皮损伤,抑制肾损伤标志物和促炎细胞因子mRNA表达,并抑制肾脏脂质过氧化及凋亡相关蛋白表达。提示曲前列尼尔可能作为保护肾脏免受缺血再灌注损伤的治疗药物。
要点
- 曲前列尼尔改善大鼠缺血再灌注后早期肾功能,降低血肌酐和尿素氮峰值并加速恢复。
- 曲前列尼尔减轻肾小管上皮损伤,抑制肾损伤标志物和促炎细胞因子mRNA表达。
- 曲前列尼尔抑制肾脏脂质过氧化及cleaved PARP-1和caspase-3、-8、-9蛋白表达。
核心结论
- 曲前列尼尔通过改善再灌注后早期肾功能、抑制肾脏炎症和肾小管上皮细胞凋亡,减轻大鼠缺血再灌注诱导的急性肾损伤。
- 曲前列尼尔有潜力作为体内保护肾脏免受缺血再灌注损伤的治疗药物。
研究设计与样本
- 雄性Sprague Dawley大鼠接受双侧肾缺血45分钟后再灌注1-168小时。
- 缺血前18-24小时皮下给予曲前列尼尔(100 ng/kg/min)或安慰剂。
主要发现
- 与I/R-安慰剂组相比,曲前列尼尔显著降低血肌酐和尿素氮峰值并加速其恢复至基线。
- 曲前列尼尔组肾小管上皮损伤的组织病理学特征较I/R-安慰剂组减轻。
- I/R-安慰剂组肾损伤标志物KIM-1和NGAL及促炎细胞因子CCL2、IL-1β、IL-6和ICAM-1的mRNA诱导表达被曲前列尼尔显著抑制。
- 曲前列尼尔显著抑制再灌注后1小时I/R-安慰剂组肾脏脂质过氧化的升高。
- 曲前列尼尔显著抑制I/R-安慰剂组肾脏cleaved PARP-1和caspase-3、-8、-9的蛋白表达。
临床怎么用
- 临床前证据提示曲前列尼尔可能用于预防或减轻缺血再灌注相关急性肾损伤,但尚未在人体验证。
局限性
- 本研究为大鼠临床前实验,结果不能直接外推至人类临床应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Renal ischemia-reperfusion injury (IRI) is a major factor causing acute kidney injury (AKI). No pharmacological treatments for prevention or amelioration of I/R-induced renal injury are available. Here we investigate the protective effects of treprostinil, a prostacyclin analog, against renal IRI in vivo. METHODS: Male Sprague Dawley rats were subjected to bilateral renal ischemia (45 min) followed by reperfusion for 1-168 h. Treprostinil (100 ng/kg/min) or placebo was administered subcutaneously for 18-24 h before ischemia. RESULTS: Treatment with treprostinil both significantly reduced peak elevation and accelerated the return to baseline levels for serum creatinine and blood urea nitrogen versus I/R-placebo animals following IRI. I/R-treprostinil animals exhibited reduced histopathological features of tubular epithelial injury versus I/R-placebo animals. IRI resulted in a marked induction of messenger RNA coding for kidney injury biomarkers, kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin and for pro-inflammatory cytokines chemokine (C-C motif) ligand 2, interleukin 1β, interleukin 6 and intracellular adhesion molecular 1 in animals treated with placebo only relative to sham controls. Upregulation of expression of all these genes was significantly suppressed by treprostinil. Treprostinil significantly suppressed the elevation in renal lipid peroxidation found in the I/R-placebo group at 1-h post-reperfusion. In addition, renal protein expression of cleaved poly(ADP-ribose) polymerase 1 and caspase-3, -8 and -9 in I/R-placebo animals was significantly inhibited by treprostinil. CONCLUSIONS: This study demonstrates the efficacy of treprostinil in ameliorating I/R-induced AKI in rats by significantly improving renal function early post-reperfusion and by inhibiting renal inflammation and tubular epithelial apoptosis. Importantly, these data suggest that treprostinil has the potential to serve as a therapeutic agent to protect the kidney against IRI in vivo.
引用
- Ding M, Tolbert E, Birkenbach M, et al. Treprostinil, a prostacyclin analog, ameliorates renal ischemia-reperfusion injury: preclinical studies in a rat model of acute kidney injury. Nephrol Dial Transplant. 2021. PMID: 33156922. doi:10.1093/ndt/gfaa236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。